EHA CAR-T Program

EHA CAR-T Program

Available on the EHA Campus, the EHA CAR-T program is an eight-course program covering all aspects of CAR-T; mechanisms of action, the process of CAR-T manufacture and infusion, treatment of hematopoietic malignancies and patient selection, CRS, and other complications as well as ethics and consent, multidisciplinary care and regulatory aspects.

Enroll now for the EHA CAR-T program

The courses in this program include interactive quizzes, links to video clips of experts, and suggestions for additional reading. This program has been peer-reviewed by Professor Hermann Einsele, Professor Maria Victoria Mateos, Professor Ulrich Jäger, Dr. Julio Delgado, and Dr. Inam Shafqat.

Current courses in the program include:  

  • Introduction to chimeric antigen receptor T-cell (CAR-T) therapy 
  • Processes in CAR-T
  • Cytokine Release Syndrome (CRS) in CAR-T: From diagnosis to management
  • Complications of CAR-T: Beyond CRS

These additional courses will become available over the next few months. 

  • CAR-T therapy for hematopoietic malignancies 
  • Ethics and consent in CAR-T 
  • Regulatory aspects of CAR-T 
  • What to expect in CAR-T

Learning Objectives

After completing this program, participants will be able to:

  1. Understand the principles, mechanism of action, and toxicities associated with CAR-T therapy

  2. Analyze the needs of hematology oncology in relation to CAR-T therapy within evidence-based practice

  3. Integrate clinical guidelines, protocols and evidence-based practice related to CAR-T treatment of hematology patients 

  4. Develop holistic care packages and treatment pathways for patients requiring CAR-T therapy, including post-discharge planning 


This program will become part of the EHA Immunotherapy program currently in development.

Last Updated on Thursday 26 November 2020.